Decrease in CD4+CD25+ and CD8+ CD28+ T cells in interstitial pneumonitis associated with rheumatic disease

Modern Rheumatology

Volumn 18, Issue 6, 2008, Pages 562-569

  Katagiri, Akira ^a   Morimoto, Shinji ^a   Nakiri, Yutaka ^a   Nakano, Souichiro ^a   Mitsuo, Akiko ^a   Suzuki, Jun ^a   Amano, Hirofumi ^a   Nozawa, Kazuhisa ^a   Asano, Masanao ^a   Tokano, Yoshiaki ^a   Hashimoto, Hiroshi ^a   Takasaki, Yoshinari ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

CD4+CD25+ regulatory T cell; CD62L; CD8+CD28 suppressor T cell; Interstitial pneumonitis; Rheumatic diseases

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; PREDNISOLONE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MIXED CONNECTIVE TISSUE DISEASE; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SUPPRESSOR CELL; SURVIVAL RATE; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD28; BLOOD CELL COUNT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; RHEUMATIC DISEASES; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 57649210151     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0090-8     Document Type: Article

References (30)

1. Kanai Y, Tokano Y, Tsuda H, Hashimoto H, Okumura K, Hirose S. HLA-DR positive T cells patients with polymyositis/dermatomyositis. J Rheumatol. 1993;20:77-9.
2. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170:655-63.
3. Piguet PF, Collart MA, Grau GE, Sappino AP, Vassalli P. Requirement of tumour necrosis factor for development of silica-induced pulmonary fibrosis. Nature. 1990;344:245-7.
4. Zhang Y, TC Lee, Guillemin B, Yu MC, Rom WN. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J Immunol. 1993;150:4188-96.
5. Chen ES, Greenlee BM, Willis-Karp M, Moller DR. Attenuation of inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. Am J Respir Cell Mol Biol. 2001;24:545-55.
6. Piguet PF, Vesin C, Grau GE, Thompson RC. Interleukin 1 receptor antagonist (IL-1 ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica. Cytokine. 1993;5:57-61.
7. Crystal RG, Bitterman PB, Mossman B, Schwarz MI, Sheppard O, Almasy L, et al. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med. 2002;166:236-46.
8. Zhu Z, Homer RJ, Wang Z, Chen O, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subpithelial fibrosis, physiolosic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779-88.
9. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med. 2001;194:809-21.
10. Smith RE, Strieter RM, Phan SH, Lukacs NW, Huffnagle GB, Wilke CA, et al. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. J Immunol. 1994;153:4704-12.
11. Kaneko Y, Kuwano K, Kunitake R, Kawasaki M, Hagimoto N. B7-1, B7-2 and class II MHC molecules in idiopathic pulmonary fibrosis and bronchiolitis obliterans-organizing pneumonia. Eur Respir J. 2000;15:49-55.
12. Lee S, Kaneko K, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol. 1998;37:1334-7.
13. Hirashima M, Fukazawa T, Abe K, Morita Y, Kusaoi M, Hashimoto H. Expression and activity analyses of CTLA-4 in peripheral blood lymphocytes in systemic lupus erythematosus patients. Lupus. 2004;13:24-31.
14. Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T, et al. Differential control of CD22 ligand expression on B and T lymphocytes, and enhanced expression in murine systemic lupus. Arthritis Rheum. 2003;48(6):1612-21.
15. Suzuki J, Nakano S, Nakiri Y Mitsuo A, Morimoto S, Tokano Y, et al. CD19/ 22 balance relates to improvement of disease activity in systemic lupus erythematosus. Mod Rheumatol. 2006;16:235-8.
16. Nakiri Y, Suzuki J, Mitsuo A, Amano H, Morimoto S, Hashimoto H, et al. Expression of CD22 on peripheral B cells in Patients with rheumatoid arthritis: Relation to CD5 positive B cells. Clin Rheumatol. 2007;26:1721-3.
17. Filaci G, Bacilieri S, Fravega M, Monetti M, Contini P, Indiveri F. Impairment of CD8+ T suppressor cell function in patients with active systemic erythematosus. J Immunol. 2001;166:6452-7.
18. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151-64.
19. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184:387-96.
20. Subcommittee for Scleroderma Criteria of the American Committee. Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum. 1980;23:581-90.
21. Arnett FC, Edwothy SM, Bloch DA, McShane DJ, Fries FJ, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
22. Kotajima L, Aotsuka S, Sumiya M, Yokohari R, Tojo T, Kasukawa R. Clinical features of patients with juvenile onset mixed connective tissue disease: Analysis of date collected in a nationwide collaborative study in Japan. J Rheumatol. 1996;23:1088-94.
23. Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975;292:344-7, 403-7.
24. Iezzi G, Sheidegger D, Lanzavecchia A. Migration and function of anti-primed nonpolarized T lymphocytes in vivo. J Exp Med. 2001;193:987-93.
25. Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, Marzo AL, et al. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. J Immunol. 2004;172:4875-82.
26. Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol. 2001;28:2389-91.
27. Fu S, Yopp AC, Mao X, Chen D, Zhanq N, Chen D, et al. CD4 + CD25 + CD62L + T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant. 2004;4:65-78.
28. Mottonen M, Heikkinen J, Mustonen L, Isomaki P, Luukkainen R, Lassila O. CD4 + CD25 + T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol. 2005;140:360-7.
29. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25 bright CD4 + regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6:R335-46.
30. Kaneko H, Saito K, Hashimoto H, Yagita H, Okumura K, Azuma M. Preferential elimination of CD28+ T cells in systemic lupus erythematosus (SLE) and the relation with activation-induced apoptosis. Clin Exp Immunol. 1996;106:218-29.